Drug Profile
AGS 009
Alternative Names: AGS-009; NNC 0152-0000-0001Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Argos Therapeutics Inc
- Class Monoclonal antibodies
- Mechanism of Action Interferon alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in USA (IV)
- 31 Dec 2013 Phase-I clinical trials in Systemic lupus erythematosus have been completed in USA (IV)
- 07 Jun 2012 Adverse events, pharmacodynamics, and pharmacokinetics data from a phase Ia trial in Systemic lupus erythematosus presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012)